Network Bio

Timeline

• 2026-08-19Network Bio launches with $50 million from Section 32, Thiel Bio, Founders Fund and others to train AI on patient tissue from academic biobanksCapital
• 2025-12-10Exai Bio's Exai-1, a model trained on small RNA fragments in blood, makes cancer classifiers work from fewer samplesLevel 3 · Checked against existing evidence

Graded by how far the evidence went, not how good the result is. See the methodology.

Founders' research on the record

Papers and results a founder of the company authored, from the timeline's bylines. Most come from before the company existed: they are the team's track record, not results the company has reported.

• 2026-10-05Arc Institute releases PIE, an open model that predicts how cells respond to a perturbation by reading what is already known about the gene, drug and cell lineLevel 2 · Computed

Graded by how far the evidence went, not how good the result is. See the methodology.

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2026-08-19Round (unnamed) · $50MconfirmedWith Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, JSL Health CapitalStated use: expand its life sciences platform for training AI models on multimodal patient data

Each round links to its line on the funding record, with its source.

Also in Biology data and tools on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-27OmabitSeed · $2MSoftware that analyses a drug developer's own preclinical, clinical and genomic data alongside published research: a scientist chooses the question in plain language and it runs the analysis and writes it up, starting with clinical development, biomarker and translational teams.
• 2026-10-26adsilicoSeries A · £10MA University of Leeds spinout whose Virtual Chimera platform builds virtual hearts and blood vessels from anonymised clinical scans with generative AI, then runs physics simulations of how a heart valve, stent or other implant behaves in each, across a population varied by age, sex, ethnicity, body size and disease.
• 2026-10-20Electric PlantSeed · $11.2MMakes electrodes and low-cost sensors that record a living plant's electrical signals from its stem or trunk, and Bombadil, a model trained on those signals across about a hundred species that estimates leaf stress measures such as photosynthetic efficiency and water stress, for farming, forestry and plant care.
• 2026-10-10BIOTREESeries B · nearly CNY 100MA mass-spectrometry service company for metabolomics and proteomics, with its own metabolite standards library. It is moving into single-cell and spatial omics and pitches that data (its MetCell single-cell metabolomics in particular) as training material for virtual-cell models.
• 2026-10-08Onyx BioSeed · $8MRuns paid, at-home research studies that measure the same people's immune systems over months and years (proteins, single-cell gene expression, metabolites, genetics) beside their clinical histories, processes every sample in its own Berkeley lab, and offers the data to biopharma and AI model developers as a 'virtual immune system'. Its first studies cover autoimmune disease and immune ageing.
• 2026-10-08OptoSeekerPre-A · over CNY 50MBuilds lab instruments that move and screen single cells with light (optoelectronic tweezers), for antibody discovery, cell-line development and cell and gene therapy. It pitches the time-stamped single-cell function data they produce as training data for AI biology models.

All 16 in this field →